CytoGenix Announces Research Agreement with DermTech International Inc. for Pre-Clinical Testing of Topical Formulations in In Vitro Human Skin Model.Business Editors/Health/Medical Writers HOUSTON--(BUSINESS WIRE)--Nov. 4, 2003 CytoGenix Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) announced Tuesday that it has signed an agreement with the DermPharm division of DermTech International Inc. a firm specializing in dermatology safety and efficacy testing with extensive experience in the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. regulatory process and in conducting studies to characterize the kinetics of various topical delivery vehicles such as those for CytoGenix' anti-herpes formulation. DermTech's scientists have over 50 years of experience in all facets of pharmacokinetic testing of skin delivered pharmaceutical and cosmetic products. The CytoGenix product studies are designed to characterize human epidermal cell Noun 1. epidermal cell - any of the cells making up the epidermis epidermis, cuticle - the outer layer of the skin covering the exterior body surface of vertebrates skin cell - any of the cells making up the skin delivery and uptake of the gene silencing DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. topical formulation against herpes. Dr. Yin Chen, chief scientist and vice president of research and development for CytoGenix, stated; "These studies of human skin kinetics will provide the data we need to optimize delivery and dosage of our anti-herpes cream as well as the other topical therapeutic products that we are developing." Paul A. Lehman, executive vice president of DermTech, manager of its DermPharm division, and co-founder of the division's predecessor states, "We welcome the opportunity to work with a molecular medicine company such as CytoGenix in assisting in their pre-clinical and clinical testing process." CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications. DermTech International since its inception in 1998 has accumulated extensive experience in both in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. and in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. testing for the FDA regulatory process. DermTech provides a competitive advantage to skin, consumer product, pharmaceutical, medical device, chemical, and biotechnology organizations worldwide through innovative consulting, pre-clinical & clinical safety and claims substantiation testing, and specializes in dermatology safety and efficacy testing. SAFE HARBOR Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the Web site at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion